Mar 28, 2011

Risk of Thrombotic Adverse Events with Subcutaneous or Inappropriate Intravenous Use of Vivaglobin (Immune Globulin Subcutaneous)

IPOPI is closely monitoring the latest developments in the United States regarding the risk of Thrombotic Adverse Events with subcutaneous or Inappropriate Intravenous use of Vivaglobin, a subcutaneous therapy for the treatment of primary humoral immunodeficiency manufactured by CSL Behring. The US Food and Drugs Administration (FDA) and CSL Behring have recently published statements providing detailed information on this matter. The statements can be found at the following links:
U.S. Food and Drug Administration statement

CSL Behring statement

World PI Week
IPOPI would be grateful for any support to the important work for primary immunodeficiencies.

Read all

Executive Director: Johan Prevot
Tel/Fax: +351 21 407 5720
UK office
Firside Main Road Downderry
Cornwall PL11 3LE
United Kingdom

Tel: +44 1503 250 668
Fax: +44 1503 250 961
IPOPI is a charity registered in the UK.
Registration No. 1058005